Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Nedrud, John G ^a   Bagheri, Nayer ^a   Schön, Karin ^b   Xin, Wei ^a   Bergroth, Hilda ^b   Eliasson, Dubravka Grdic ^b   Lycke, Nils Y ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIUM LYSATE; CHOLERA TOXIN A1 SUBUNIT DD VACCINE ADJUVANT; CYSTEINYLHISTIDINYLHISTIDINYLLEUCYLASPARTYLLYSYLSERYLISOLEUCYLLYSYLGLUTAMYLASPARTYLVALYLGLUTAMINYLPHENYLALANYLALANYLASPARTYLSERYLARGINYLISOLEUCINE; EPITOPE; HELICOBACTER PYLORI VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; PHENYLALANYLVALYLASPARTYLGLYCYLLYSYLGLUTAMYLVALYLTYROSYLSERYLLYSYLPROPYLALANYLASPARAGINYLLYSYLVALYLSERINE; UNCLASSIFIED DRUG; UREASE B CLASS II PEPTIDE; VALYLALANYLASPARTYLLYSYLTYROSYLASPARTYLVALYLGLUTAMINYLVALYLALANYLISOLEUCYLHISTIDINYLTHREONYLASPARTYLTHREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL IMMUNITY; DRUG EFFICACY; DRUG SAFETY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; INFECTION PREVENTION; MOUSE; NONHUMAN; PLASMID; STOMACH MUCOSA; TH1 CELL; TH17 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHOLERA TOXIN; EPITOPES, T-LYMPHOCYTE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; UREASE; VACCINES, SUBUNIT;

EID: 84896733087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083321     Document Type: Article

References (47)

1. NIH Consensus Conference (1994) Helicobacter pylori in peptic ulcer disease. Journal of the American Medical Association 272: 65-69.
2. World Health Organization (1994) Infection with Helicobacter pylori. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer. pp. 177-241.
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, et al. (2012) Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61: 646-664.
4. Tepes B, O'Connor A, Gisbert JP, O'Morain C (2012) Treatment of Helicobacter pylori infection 2012. Helicobacter 17 Suppl 1: 36-42.
5. Blanchard TG, Nedrud JG (2010) Helicobacter pylori Vaccines. In: Sutton P, Mitchell H, editors. Helicobacter Pylori in the 21st Century. Wallingford, Oxfordshire, United Kingdom: CAB International. pp. 167-189.
6. Czinn SJ, Blanchard T (2011) Vaccinating against Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol 8: 133-140.
7. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG (2003) Vaccine-Induced Reduction of Helicobacter pylori Colonization in Mice Is Interleukin-12 Dependent but Gamma Interferon and Inducible Nitric Oxide Synthase Independent. Infect Immun 71: 910-921. (Pubitemid 36150787)
8. Raghavan S, Ostberg AK, Flach CF, Ekman A, Blomquist M, et al. (2010) Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infect Immun 78: 4251-4260.
9. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud JG, et al. (1998) MHC-class II but not MHC-class I or B cell responses are required for vaccine-induced protection against murine Helicobacter pylori infection. Abstracts to Third International Workshop on Pathogenesis and Host Response in Helicozbcter Infections, Helsingor, Denmark.
10. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, et al. (1999) Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cellular Immunology 191: 74-80. (Pubitemid 29054969)
11. Pappo J, Torrey D, Castriotta L, Savinainen A, Kabok Z, et al. (1999) Helicobacter pylori Infection in Immunized Mice Lacking Major Histocompatibility Complex Class I and Class II Functions. Infect Immun 67: 337-341. (Pubitemid 29021667)
12. Sutton P, Wilson J, Kosaka T, Wolowczuk I, Lee A (2000) Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 78: 28-30. (Pubitemid 30090986)
13. Akhiani AA, Schon K, Franzen LE, Pappo J, Lycke N (2004) Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 172: 5024-5033. (Pubitemid 38456429)
14. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney AC, et al. (1995) Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109: 115-121.
15. Gomez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, et al. (1998) Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 16: 460-471. (Pubitemid 28044163)
16. Smythies LE, Novak MJ, Waites KB, Lindsey JR, Morrow CD, et al. (2005) Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23: 901-909. (Pubitemid 39643178)
17. Hirota K, Nagata K, Norose Y, Futagami S, Nakagawa Y, et al. (2001) Identification of an antigenic epitope in Helicobacter pylori urease that induces neutralizing antibody production. Infect Immun 69: 6597-6603. (Pubitemid 32995413)
18. Shi Y, Wu C, Zhou WY, Mao XH, Guo G, et al. (2007) Identification of H-2d restricted Th epitopes in Urease B subunit of Helicobacter pylori. Vaccine 25: 2583-2590. (Pubitemid 46400931)
19. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, et al. (1999) Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116: 804-812. (Pubitemid 29153528)
20. Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, et al. (1998) Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16: 33-37. (Pubitemid 27504801)
21. Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, et al. (2010) Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28: 1404-1411.
22. Ågren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY (1999) Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosylatransferase and Ig-binding activity. Journal of Immunology 162: 2432-2440. (Pubitemid 29288873)
23. Ågren LC, Ekman L, Löwenadler B, Lycke NY (1997) Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. Journal of Immunology 158: 3936-3946. (Pubitemid 127488754)
24. Eriksson AM, Schon KM, Lycke NY (2004) The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues. J Immunol 173: 3310-3319. (Pubitemid 39142040)
25. Sundling C, Schon K, Morner A, Forsell MN, Wyatt RT, et al. (2008) CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 89: 2954-2964.
26. Akhiani AA, Stensson A, Schon K, Lycke N (2006) The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 63: 97-105.
27. Lycke N, Bemark M (2010) Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins. Mucosal Immunol.
28. Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, et al. (2008) CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26: 1243-1252.
29. Eliasson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, et al. (2011) A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29: 3951-3961.
30. Blanchard TG, Nedrud JG (2012) Laboratory Maintenance of Helicobacter Species. Current Protocols in Microbiology 24: 8B.1.1-8B.1.19.
31. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, et al. (2002) Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17: 375-387. (Pubitemid 35279557)
32. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, et al. (1997) A standardised mouse model of Helicobacter pylori infection. Introducing the Sydney strain. Gastroenterology 112: 1386-1397. (Pubitemid 27157555)
33. Garhart CA, Redline RW, Nedrud JG, Czinn SJ (2002) Clearance of Helicobacter pylori infection and resolution of post immunization gastritis in a kinetic study of prophylactically immunized mice. Infection and Immunity 70: 3529-3538. (Pubitemid 34665989)
34. DeLyria ES, Redline RW, Blanchard TG (2009) Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136: 247-256.
35. Zhao W, Wu W, Xu X (2007) Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice. Vaccine 25: 7664-7673. (Pubitemid 47538813)
36. Spangler BD (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiological Reviews 56: 622-647.
37. Delyria ES, Nedrud JG, Ernst PB, Alam MS, Redline RW, et al. (2011) Vaccine-Induced Immunity Against Helicobacter pylori in the Absence of IL-17A. Helicobacter 16: 169-178.
38. Flach C-F, Ostberg AK, Nilsson A-T, Malefyt RDW, Raghavan S (2011) Proinflammatory Cytokine Gene Expression in the Stomach Correlates with Vaccine-Induced Protection against Helicobacter pylori Infection in Mice: an Important Role for Interleukin-17 during the Effector Phase. Infect Immun 79: 879-886.
39. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, et al. (2009) Interleukin 17 is a Critical Mediator of Vaccine-Induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136: 2237-2246 e2231.
40. Sutton P, Chionh YT (2013) Why can't we make an effective vaccine against Helicobacter pylori? Expert Rev Vaccines 12: 433-441.
41. Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G (2003) The quest for a vaccine against Helicobacter pylori/how to move from mouse to man? Microbes Infect 5: 749-756. (Pubitemid 36695150)
42. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, et al. (2008) Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135: 787-795.
43. Every AL (2013) Key host-pathogen interactions for designing novel interventions against Helicobacter pylori. Trends Microbiol.
44. Flach CF, Svensson N, Blomquist M, Ekman A, Raghavan S, et al. (2011) A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 29: 1235-1241.
45. Yang WC, Chen L, Li HB, Li B, Hu J, et al. (2013) Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects. Vaccine 31: 1204-1209.
46. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, et al. (2009) Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 27: 5013-5019.
47. Ding H, Nedrud JG, Blanchard TG, Zagorski BM, Li G, et al. (2013) Th1-Mediated Immunity against Helicobacter pylori Can Compensate for Lack of Th17 Cells and Can Protect Mice in the Absence of Immunization. PLoS One 8: e69384.